MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

This study enrolls patients who have experienced local recurrence of nasopharyngeal carcinoma (NPC) with or without regional recurrence. The treatment regimen includes an induction phase with MRG003 at 2.0 mg/kg (D1) combined with Tislelizumab 200 mg (D1), administered weekly for 6 cycles. This is followed by maintenance therapy consisting of Capecitabine (650 mg/m², twice daily on days 1-21) in combination with Tislelizumab, continued for up to 1 year or until disease progression.

Trial Details

NCT ID
NCT07331428
Phase
PHASE2
Sponsor
Fujian Cancer Hospital
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • MRG003
  • Tislelizumab
  • Capecitabine
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611

Key Eligibility Criteria

  • \*\*Inclusion Criteria:\*\*
  • Patients with locally recurrent nasopharyngeal carcinoma (NPC) more than 1 year after initial radical treatment for non-metastatic NPC, with or wit…
  • Age 18-70 years.
  • Pathologically confirmed local recurrence of NPC, staged as rT1-rT4 according to the 9th edition of the AJCC/UICC classification.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →